Vanda Pharmaceuticals (VNDA) to Release Earnings on Wednesday

Vanda Pharmaceuticals (NASDAQ:VNDA) is set to release its earnings data after the market closes on Wednesday, July 31st. Persons interested in listening to the company’s earnings conference call can do so using this link.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by ($0.12). Vanda Pharmaceuticals had a negative return on equity of 0.90% and a negative net margin of 2.75%. The firm had revenue of $47.46 million for the quarter, compared to analysts’ expectations of $48.50 million.

Vanda Pharmaceuticals Trading Down 1.7 %

Shares of NASDAQ VNDA traded down $0.10 during midday trading on Tuesday, reaching $5.90. 120,286 shares of the company were exchanged, compared to its average volume of 1,655,992. Vanda Pharmaceuticals has a 1 year low of $3.30 and a 1 year high of $6.75. The stock has a fifty day simple moving average of $5.73 and a 200 day simple moving average of $4.80. The stock has a market cap of $343.38 million, a P/E ratio of -75.00 and a beta of 0.75.

Wall Street Analyst Weigh In

VNDA has been the topic of a number of research reports. Cantor Fitzgerald initiated coverage on Vanda Pharmaceuticals in a report on Thursday, July 11th. They set an “overweight” rating and a $11.00 price target on the stock. StockNews.com initiated coverage on Vanda Pharmaceuticals in a report on Sunday. They set a “hold” rating on the stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.